Overview
Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020.
Indication
Tazemetostat is indicated to treat adult and pediatric patients 16 years and older with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection. It is also indicated to treat adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an IZH2 mutation and who have received at least 2 prior systemic therapies. Additionally, it is indicated in adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Associated Conditions
- Locally Advanced Epithelioid Sarcoma
- Metastatic Epithelioid Sarcoma
- Refractory Follicular Lymphoma
- Relapsed Follicular Lymphoma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/02/13 | Phase 1 | Recruiting | |||
2024/11/18 | Phase 2 | Recruiting | Eric Jacobsen, MD | ||
2024/08/28 | Phase 2 | Recruiting | City of Hope Medical Center | ||
2024/02/05 | Phase 2 | Active, not recruiting | |||
2023/10/05 | Phase 2 | Not yet recruiting | |||
2023/08/16 | Phase 2 | Recruiting | |||
2023/08/09 | Phase 1 | Not yet recruiting | |||
2023/07/07 | Phase 1 | Recruiting | |||
2023/06/06 | Phase 2 | Recruiting | |||
2023/02/06 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Epizyme, Inc. | 72607-100 | ORAL | 200 mg in 1 1 | 12/21/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.